
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:18 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/33/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/33/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../../covid-19.hbs.hu/index.html" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/332679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1388</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="33">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="33">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/jH2"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Managing%20chronic%20bladder%20diseases%20with%20the%20administration%20of%20exogenous%20glycosaminoglycans-%20an%20update%20on%20the%20evidence%202016%20Urology&amp;url=https://hbs.hu/r/jH2"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/jH2&amp;title=Managing%20chronic%20bladder%20diseases%20with%20the%20administration%20of%20exogenous%20glycosaminoglycans-%20an%20update%20on%20the%20evidence%202016%20Urology&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/jH2"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/33?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="33" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>2. Therapeutic Advances in Urology  8(2)  92   http://tau.sagepub.com damage of its glycosaminoglycan (GAG) compo - nent [Parsons, 2007]. A ‘cascade’ of events start - ing from GAG injury, which fails to heal, may lead  to chronic bladder epithelial damage and neuro - genic inflammation. Promptly restoring the GAG  layer to prevent the cycle of inflammation and  hypersensitization is one of the bases for the treat - ment of chronic cystitis and PBS/IC [Han  et  al.   2015]. We performed a systematic review using and  matching different keywords: ‘bladder’, ‘urothe - lium’, ‘glycosaminoglycans’, ‘functional disor - ders’, ‘cystitis’, ‘bladder pain’, ‘therapy’, ‘chronic  bladder diseases’, ‘chemotherapy’ and ‘radiother - apy’. The research was performed using Medline  (through PubMed), Embase, Web of Science and  Cochrane Review databases; the search was  developed from inception to 31 May 2015. In  addition, we tried to obtain details of registered  but not yet published trials. We selected and  reported the most recent and updated evidence  with GAGs replenishment for different pathologi - cal conditions involving the lower urinary tract.  The aim of our paper was to provide the reader  with the latest information about the clinical use  of GAG therapy starting from the pathophysio - logical principles. Pathophysiology of GAG damage Different causes may be considered in the early  stage of GAG injury. Autoimmune diseases,  chronic bacterial infections, chemicals, anticancer  drugs such as cyclophosphamide or Bacillus  Calmette-Guérin (BCG) exposure, and radiation  exposure can all result in urothelial GAG loss.  Damaging this shielding layer results in the loss of  ‘watertight’ function and allows both normal (i.e.  H + , K + , Na + , Cl - ) and abnormal constituents of  urine (i.e. metabolites of cytotoxic drugs or toxic  substances excreted into it) to come into direct  contact with the subepithelial layers. This infiltra - tion through the GAG barrier defect can cause  subepithelial layer inflammation and delay or pre - vent the healing of the damaged bladder urothelial  cells as well as the GAGs [Hurst  et al.  1996]. The  net result is the activation of a subset of unmyeli - nated C-fibres in the suburothelium [Maggi and  Meli, 1988]. They are peptide-containing fibres  (substance P, neurokinins A and B, calcitonine  gene related peptide and bradykinin) and they  result selectively sensitive to capsaicin, the pungent  ingredient of red chilli [Maggi and Meli, 1988].  Although they serve as primary afferents, they may  play an important role in the regulation of the  lower urinary tract by an efferent function showing  a characteristic ‘double function’ [Maggi and Meli,  1988]. The afferent function, mediated by the  release of neuropeptides from their central end - ings, is involved in the regulation of micturition  reflex, pain sensation and activation of visceral  reflex. The efferent function, due to the release of  substance P, calcitonin gene related peptide and  tachykinins from peripheral endings, regulates the  smooth muscle contraction, immunocell migra - tion, mast cells degranulation and neurogenic  inflammation. They are actively involved in the  cotransmission phenomenon (axons release more  than one transmitter for each action potential), in  neuromodulation (locally released agents may  modulate the amount of neurotransmitters released  prejunctionally) and in nervous system plasticity  during development, aging, chronic inflammation  and spinal cord injury (neuroplasticity) [Lazzeri,  2009]. Evidence supports their role in bladder  chronic inflammation [Sculptoreanu  et  al.  2005].  The activation of sensory fibres due to the defect of  GAGs, which would allow the back flow of irri - tants in the submucosa, is involved in the increase  of frequency in chronically inflamed bladders.  Capsazepine, which is a selective capsaicin antago - nist, decreased the frequency of reflex contractions  in cyclophosphamide inflamed rat urinary blad - ders [Dinis  et al.  2004]. When the GAG defect persists or its healing pro - cess fails, chronic stimulation of suburothelial tis - sues may result in visceral hypersensitivity of  bladder C-fibres nociceptors [Doyle  et al.  1997].  Clinically, the neuronal hypersensitivity, the  exaggerated perception to normal stimuli, leads  to allodynia, the perception of nociceptive stimu - lation which occurs for stimuli that would usually  evoke an innocuous sensation (i.e. pain during  bladder filling) and to hyperalgesia: exaggerated  pain sensation to a stimulation which is normally  mildly noxious (i.e. high pain intensity for mild  inflammation). Under these conditions, the cen - tral nervous system receives an increased afferent  barrage from peripheral bladder nervous endings.  This barrage, in turn, triggers central mechanisms  that amplify and sustain the effect of the sensory  nerve peripheral input, leading to molecular  changes in the peripheral organs and in the cen - tral nervous system [Doyle  et  al.  1997]. It has  been observed that changes in density of neuro - peptides in sensory nerves develop over a period  of 5–7 days and that they are preceded by changes  in level of activation of transcription factors.  </p>
                                        
                                            <p>3. M Lazzeri, R Hurle  et al. http://tau.sagepub.com   93 Changes of the level of transcription factor c-jun  and Oct-2 were found early in the inflammation  conditions and the consequences were an increase  of neuronal growth [Doyle  et  al.  1997]. The  nuclear factor  κ B (NF- κ B), known to exist in an  inducible form in a wide range of eukaryotic cells,  is activated by inflammatory mediators and has  been thought to be responsible for hypersensibil - ity. The direct consequence of all these changes is  an increase of neuropeptide synthesis and their  release at the level of synapses. Clinically the  increase of release of neuropeptides at the level of  bladder will produce chronic pain, an increase of  frequency, nocturia and urgency, and sustain a  neurogenic inflammation, while at the level of  central nervous system it will lead to selective  expression of genes (i.e. c-fos) [Doyle  et al.  1997].  A nerve sprouting will be observed in the grey  matter of the dorsal horn of the spinal cord with  an increase in craniocaudal and latero-lateral syn - apses resulting in hypersensibility [Carter  et  al.   1996]. According to these theories, the early  repair of the GAG layer by exogenous hyaluronic  acid (HA) and chondroitin sulfate (CS), both  mucopolysaccharides which act by different  mechanisms of action, inhibition of adherence of  immune complexes to polymorphonuclear cells,  inhibition of leukocyte migration and aggrega - tion, regulation of fibroblast and endothelial cell  proliferation, and enhancement of connective tis - sue healing [Iavazzo  et  al.  2007], might avoid  chronic evolution of bladder inflammation. Clinical evidence Urinary tract infections Almost 50% of women will experience at least  one urinary tract infection (UTI) in their lifetime  and, in 20–50% of these, the episode is followed  by a second infection within 6 months [Laupland  et  al.  2007]. In the US, up to 15% of women  develop UTIs each year, and 1 in 4 of those will  have  ⩾ 1 recurrences. This condition is not, how - ever, restricted to women, and it is estimated that  the annual incidence of UTIs in males aged 17– 79 years in the US is 2.2% [Guay, 2008]. The  symptoms of UTIs, particularly when recurrent,  impact on quality of life and productivity, affect - ing physical and emotional functioning, vitality,  sexual and social functioning, and general health  perceptions [Foxman, 2002]. Eradication of the infection has been the aim of  current management strategies. Continuous or  patient-initiated antimicrobial therapy is the cur - rent standard management practice for the treat - ment of acute UTIs and the prophylaxis of  recurrent UTIs [European Association of  Urology, 2015]. Agents include trimethoprim  with or without sulfamethoxide, nitrofurantoin,  cefaclor, cephalexin, norfloxacin, ciprofloxacin  and fosfomycin. The disadvantages of this choice  of treatment include the adverse effects associ - ated with the antimicrobial agents and the increas - ing drug resistance [Sorlozano  et al.  2014]. Despite our broad array of very successful antimi - crobial agents, UTIs remain a complex clinical  condition. These may present different severities,  be acute or chronic, symptomatic or asympto - matic, be community or nosocomial acquired,  and be sporadic or recurrent. The relationship  between the host and uropathogens is pivotal in  the initiation, development, maintenance and  recurrence of UTIs, and an understanding of this  interaction is therefore important in the preven - tion of the chronic or recurrent UTIs. On the  uropathogen side, the virulence of the interaction  between the uropathogen and host is determined  by one or more factors, including adhesins,  siderophore systems, biofilms, toxins, autotrans - porters, lipopolysaccharides, capsules, flagella or  fimbria, metabolic traits, urease and pathog - enomics. On the host side, the defence mecha - nisms contributing to the bladder’s natural  resistance to bacterial colonization include the  regular flushing of the bladder, and the pH and  osmolality of urine, which does not support bac - terial growth. In addition, urothelial GAGs also  play an important role in fending off infection, by  virtue of them forming a physical barrier. This  class of polysaccharides has hydrorepellant prop - erties, making the inner bladder wall impervious  to urine contents. Key components of this GAG  layer are HA and CS. There is a range of commercially available intra - vesical formulations of these components, alone  or in combination. There are formulations con - taining a low concentration of HA (0.08%), a low  concentration of CS (0.2%) or a high concentra - tion of CS (2%). Exogenous GAGs, especially in  the combination of HA and CS [Ialuril ® , Institute  Biochimique (IBSA)], were originally investi - gated for efficacy in patients with PBS/IC who  had not benefited from other therapies [Cervigni  et  al.  2008], but more recent studies showed its  efficacy in the prevention of recurrent UTIs in  patients who had at least three episodes of  </p>
                                        
                                            <p>1. Ther Adv Urol 2016, Vol. 8(2) 91   –99 DOI: 10.1177/   1756287215621234 © The Author(s), 2015.    Reprints and permissions:    http://www.sagepub.co.uk/ journalsPermissions.nav Therapeutic Advances in Urology http://tau.sagepub.com   91 Introduction One of the main purposes of physicians is to dis - cover and deliver safe, effective and affordable  treatments to patients based on their need. Acute  and chronic cystitis due to bacteria, chemical or  physical irritants which cause mucosal inflamma - tion remain highly distressing conditions that  urologists, gynaecologists and other caregivers  find difficult to manage [Lazzeri and Montorsi,  2011]. Owing to different and often uncertain  causes and aetiology, as in the case of painful blad - der syndrome (PBS) or interstitial cystitis (IC), a  clinical condition characterized by complaint of  suprapubic pain related to bladder filling, accom - panied by other symptoms such as increased day - time and night-time frequency, most of the  strategies used to alleviate symptoms have had  disappointing results in the absence of proven  urinary infection or other pathologies [Hanno  et al.  2011]. Although the pathophysiology of acute chronic  cystitis and other ‘sensory’ disorders, i.e. PBS/IC,  often remains multifactorial, there is a wide con - sensus that such clinical conditions may arise from  a primary defective urothelium lining or from a  Managing chronic bladder diseases  with the administration of exogenous  glycosaminoglycans: an update on the  evidence Massimo Lazzeri, Rodolfo Hurle, Paolo Casale, NicolòMaria Buffi, Giovanni Lughezzani,  Girolamo Fiorini, Roberto Peschechera, Luisa Pasini, Silvia Zandegiacomo, Alessio Benetti,  Gianluigi Taverna, Giorgio Guazzoni and Guido Barbagli Abstract :   Although the pathophysiology of acute chronic cystitis and other ‘sensory’ disorders,  i.e. painful bladder syndrome (PBS) or interstitial cystitis (IC), often remains multifactorial,  there is a wide consensus that such clinical conditions may arise from a primary defective  urothelium lining or from damaged glycosaminoglycans (GAGs). A ‘cascade’ of events  starting from GAG injury, which fails to heal, may lead to chronic bladder epithelial damage  and neurogenic inflammation. To restore the GAG layer is becoming the main aim of new  therapies for the treatment of chronic cystitis and PBS/IC. Preliminary experiences with GAG  replenishment for different pathological conditions involving the lower urinary tract have  been reported. There is a range of commercially available intravesical formulations of these  components, alone or in combination. Literature evidence shows that exogenous intravesical  hyaluronic acid markedly reduces recurrences of urinary tract infections (UTIs). Patients  treated with exogenous GAGs have fewer UTI recurrences, a longer time to recurrence and  a greater improvement in quality of life. Exogenous intravesical GAGs have been used for the  treatment of PBS/IC. Despite the limitations of most of the studies, findings confirmed the role  of combination therapy with hyaluronic acid and chondroitin sulfate as a safe and effective  option for the treatment of PBS/IC. To prevent and/or treat radiotherapy and chemotherapy  induced cystitis, GAG replenishment therapy has been used showing preliminary encouraging  results. The safety profile of exogenous GAGs has been reported to be very favourable, without  adverse events of particular significance. Keywords:   urothelium, cystitis, glycosaminoglycans, therapy Correspondence to:   Massimo Lazzeri, MD, PhD     Department of Urology,  Istituto Clinico Humanitas  IRCCS, Clinical and  Research Center, via  Manzoni 56, 20089  Rozzano, MI, Italy  <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="0d606c7e7e64606223616c7777687f644d">[email&#160;protected]</a> humanitas.it Rodolfo Hurle, MD   Paolo Casale, MD   NicolòMaria Buffi, MD   Giovanni Lughezzani, MD   Girolamo Fiorini, MD   Roberto Peschechera, MD   Luisa Pasini, MD   Silvia Zandegiacomo, MD   Alessio Benetti, MD   Gianluigi Taverna, MD   Department of Urology,  Istituto Clinico Humanitas  IRCCS, Clinical and  Research Center, Rozzano,  MI, Italy  Giorgio Guazzoni     Department of Urology,  Istituto Clinico Humanitas  IRCCS, Clinical and  Research Center,  Humanitas University,  Rozzano, MI, Italy Guido Barbagli, MD   Centro Chirurgico  Toscano, Arezzo, Italy 621234 TAU 0 0 10.1177/1756287215621234 Therapeutic Advances in UrologyM Lazzeri, R Hurle research-article 2015 Review </p>
                                        
                                            <p>5. M Lazzeri, R Hurle  et al. http://tau.sagepub.com   95 of CS 2.0% over control after 6 weeks of treat - ment [Nickel  et al.  2010]. Porru and colleagues investigated the efficiency of  intravesical CS/HA combination in 20 PBS/IC  patients. Visual analogue scale (VAS) for pain  and urgency, number of void per day, mean void - ing volume, Interstitial Cystitis Symptom Index  (ICSI) and PUF questionnaire improved com - pared with baseline [Porru  et al.  2012]. Cervigni  and colleagues seemed to confirm such results.  They reported the long-term results of intravesi - cal CS/HA therapy in 12 patients and showed the  sustained efficiency for 3 years in terms of mean  number of voids per day and mean volume per  void with the confirmation of quality of life assess - ments [Cervigni  et  al.  2012]. The same group  confirmed such results in 2014 [Cervigni  et  al.   2014]. In this study 73 patients were treated with  Ialuril and 35 with RIMSO-50 ® . At baseline,  mean pain VAS scores of 65.88 [standard devia - tion (SD) 20.93] and 64.14 (SD 20.66) were  reported in the Ialuril and the RIMSO-50 groups,  respectively. At the end-of-treatment visit, the  response to treatment in terms of pain decrease  from baseline was statistically significant in both  groups, with a VAS score reduction of -39.53  (SD 24.58) for Ialuril and of -31.89 (SD 26.22)  for RIMSO-50. For the 59 patients in the Ialuril  and the 31 patients in the RIMSO-50 group com - pleting the follow-up period, the mean VAS  reduction was -43.71 (SD 28.56) and -33.65 (SD  31.31), respectively. The results from voiding  diaries and the questionnaire scores were consist - ent with pain reduction. There was a higher pro - portion of patients with adverse events in the  RIMSO-50 [28.6%; 95% confidence intervals  (CI) 13.61–43.45) than in the Ialuril (15%; 95%  CI 6.86–23.27) group. A case of strangury and a  case of sovrapubic pain, both treatment-related,  led to withdrawal of two patients, one per group. Despite the limitations of most of those studies,  the findings confirmed the role of combination  therapy with HA and CS as a safe and effective  option for the treatment for PBS/IC. Chemotherapy and radiotherapy induced  cystitis Cystitis can be induced by both radiotherapy and  chemotherapy, and can be either acute or chronic  [Payne  et al.  2013]. The condition often results in  storage type lower urinary tract symptoms and  haematuria. It is generally thought that damage to  the GAG layer coating the urothelium is the ini - tial trigger for the development of cystitis. In  order to prevent and/or treat such conditions,  GAG replenishment therapy with CS, heparin,  HA and a new combination of CS and HA (Ialuril,  IBSA) have been used. Shao and colleagues randomized 36 patients  undergoing radiotherapy for gynaecological  malignancies to receive either HA or hyperbaric  oxygen therapy (HBOT) [Shao  et al.  2012]. They  found no significant differences between the two  groups in terms of haematuria, voiding frequency  or VAS pain at 6, 12 and 18 months after treat - ment, except for a decreased frequency of voiding  at 12 months in the HA group. Sommariva and colleagues studied the effects of  intravesical HA  +  CS in patients with sympto - matic late radiation tissue cystitis [Sommariva  et al.  2014]. In this 12-month, prospective, longi - tudinal, nonrandomized, investigative pilot study,  patients with severe haematuria received daily  instillations 5 days/week in the first month, 3 days/ week in the second month, 2 days/week in the  third month, once weekly in months 4−6, every 2  weeks in months 7−8, every 3 weeks in months  9−10 and monthly/bimonthly for 1 year. Patients  without or with occasional haematuria received  instillations 3 days/week in the first month, 2 days/ week in the second month, 1 day/week in months  3−4, every 2 weeks in months 5−6, every 3 weeks  in months 7−8 and monthly/bimonthly for 1 year.  A total of 32 patients were enrolled. The authors  found interesting results. Starting from a mean  baseline of 66.9 ml, bladder capacity significantly  increased to 101.9 ml at 3 months and to 174.4 ml  at 12 months ( p   &lt;  0.05 for both  versus  baseline).  Voiding frequency also significantly decreased  from 14.6 per day at baseline to 10.5 per day at  month 3 and 8.8 per day at month 12 ( p   &lt;  0.001  for both  versus  baseline). Significant increases  were observed after 3 and 12 months for the qual - ity of life as measured by the EQ-5D™ and EQ-5D  VAS. However, the fact that the Sommariva study  is not a RCT and does not include a control group  limits clear conclusions. Other factors, such as a  more intense schedule treatment, a prevalence of  male population, different types of tumour than  those investigated in previous available studies,  require further investigations to better define the  feasibility of a tailored-made therapy. Giannessi and colleagues investigated a group of  patients with cystitis and nocturia related to post  </p>
                                        
                                            <p>7. M Lazzeri, R Hurle  et al. http://tau.sagepub.com   97 all follow-up times, significant improvements  were seen in VAS scores for pain and urgency,  voids per 24 hours, and urine volume per void  (Table 1). Significant improvements were  observed throughout the 12-week study period.  These authors concluded that intravesical instilla - tion of HA  +  CS is an efficacious strategy for  refractory BCG-induced chemical cystitis with  results that appear to be long-lasting. Finally Topazio and colleagues investigated if  sequential administration of HA could reduce the  side effects related to BCG [Topazio  et al.  2014]  A total of 30 consecutive subjects undergoing  BCG intravesical administration for high risk  NMIBC were randomized to receive either BCG  alone or BCG and HA. The mean VAS for pain  was significantly lower in the group receiving the  combination of BCG and HA. The International  Prostate Symptom Score (IPSS) and the number  of daily micturitions were all significantly lower in  the group receiving BCG and HA Conclusion Robust evidence indicates that a defective urothe - lial barrier may underlie or be involved in the  pathogenesis of several chronic bladder conditions  such as PBS/IC, recurrent UTIs, and chemical and  radiation cystitis. These different clinical entities,  which in the past were considered distinct diseases,  can now be viewed as diseases caused as a result of  the dysfunction of a common physiological ele - ment, the urothelium and associated GAG lining. This renewed approach to looking at the patho - physiology of these GAG disorders will allow the  development of more effective treatments for these  debilitating and sometimes chronic diseases.  Preliminary studies of the intravesical instillation of  a combined solution containing a high concentra - tion of HA and CS as GAG replacement therapy  suggest that this formulation has efficacy potential  in both UTIs and PBS/IC. Importantly, the safety  profile of this combination has been reported to be  very favourable, without adverse events of particu - lar significance. New emerging oral formulations  could be a noninvasive and complementary  approach, although no evidence yet exists. Funding This research received no specific grant from any  funding agency in the public, commercial, or not- for-profit sectors. Conflict of interest statement The authors declare that there are no conflicts of  interest. References Adile, B., Calagna, G., Adile, G., Granese, R., Polito,  S., Saitta, S.  et al . (2014) Usefull of intravesical  instillation of hyaluronic acid and chondroitin  sulphate in preventing recurrent bacterial cystitis. ICS  2014, 20–24 October 2014, Rio de Janeiro, abstract  577. Bassi, P., Costantini, E., Foley, S. and Palea, S.  (2011) Glycosaminoglycan therapy for bladder  diseases: emerging new treatments review article.  Eur  Urol  10: 451–459. Carter, B., Kaltschmidt, C., Kaltschmidt, B.,  Offenhäuser, N., Böhm-Matthaei, R., Baeuerle, P.   et al . (1996) Selective activation of NF-kappa B by  nerve growth factor through the neurotrophin receptor  p75.  Science  272: 542–545. Cervigni, M., Natale, F., Nasta, L. and Mako, A.  (2012) Intravesical hyaluronic acid and chondroitin  sulphate for bladder pain syndrome/interstitial cystitis:  Long-term treatment results.  Int Urogynecol J  23:  1187–1192. Cervigni, M., Natale, F., Nasta, L., Padoa, A., Voi, R.  and Porru, D. (2008) A combined intravesical therapy  with hyaluronic acid and chondroitin for refractory  painful bladder syndrome/interstitial cystitis.  Int  Urogynecol J Pelvic Floor Dysfunct  19: 943–947. Cervigni, M., Sommariva, M., Porru, D., Ostardo,  E., Tenaglia, R., Giammò, A.  et al . (2014) A  randomized, open-label, multicentre study of  efficacy and safety of intravesical hyaluronic acid and  chondroitin sulfate (HA 1.6% and CS 2%)  versus   dimethyl sulfoxide (DMSO 50%) in women with  bladder pain syndrome/interstitial cystitis (BPS/IC).  Eur Urol  13: e464. Cicione, A., Cantiello, F., Ucciero, G., Salonia, A.,  Torella, M., De Sio, M.  et al . (2014) Intravesical  treatment with highly-concentrated hyaluronic acid  and chondroitin sulphate in patients with recurrent  urinary tract infections: results from a multicentre  survey.  Can Urol Assoc J  8: E721–E727. Constantinides, C., Manousakas, T., Nikolopoulos,  P., Stanitsas, A., Haritopoulos, K. and Giannopoulos,  A. (2004) Prevention of recurrent bacterial cystitis by  intravesical administration of hyaluronic acid: a pilot  study.  BJU Int  93: 1262–1266. Costantini, E., Lazzeri, M., Pistolesi, D., Del  Zingaro, M., Frumenzio, E., Boni, A.  et al . (2013)  Morphological changes of bladder mucosa in patients  </p>
                                        
                                            <p>9. M Lazzeri, R Hurle  et al. http://tau.sagepub.com   99 Lazzeri, M. and Montorsi, F. (2011) The therapeutic  challenge of ‘chronic cystitis‘: search well, work  together, and gain results.  Eur Urol  60: 78–80. Li Marzi, V., Del Popolo, G., Maurelli, V., Cocci,  A., Perugia, C., Bove, P.  et al . (2013) Intravescical  administration of hyaluronic acid plus chondroitin  sulphate to reduce local bacillus calmette guerin  (BCG) toxicity: a randomized prospective pilot study.  ICS 2013, 26–30 August 2013, Barcelona, Spain:  abstract 554. Lipovac, M., Kurz, C., Reithmayr, F., Verhoeven,  H., Huber, J. and Imhof, M. (2007) Prevention  of recurrent bacterial urinary tract infections by  intravesical instillation of hyaluronic acid.  Int J  Gynaecol Obstet  96: 192–195. Maggi, C. and Meli, A. (1988) The sensory efferent  function of capsaicin-sensitive neurons.  Gen Pharmac   19: 1–43. Morales, A., Emerson, L., Nickel, J. and Lundie, M.  (1996) Intravesical hyaluronic acid in the treatment of  refractory interstitial cystitis.  J Urol  156: 45–48. Morelli, M., Mocciaro, R., Venturella, R., Albano,  A., Sacchinelli, A. and Zullo, F. (2015) Hyaluronic  acid-chondroitin sulfate: a potential factor to select  pure stress urinary incontinence in patients with  interstitial cystitis⁄painful bladder syndrome and  mixed incontinence symptoms.  Minerva Ginecol  67:  121–125. Nickel, J., Egerdie, R., Steinhoff, G., Palmer, B.  and Hanno, P. (2010) A multicenter, randomized,  double-blind, parallel group pilot evaluation of the  efficacy and safety of intravesical sodium chondroitin  sulphate  versus  vehicle control in patients with  interstitial cystitis/painful bladder syndrome.  Urology   76: 804–809. Parsons, C. (2007) The role of the urinary epithelium  in the pathogenesis of interstitial cystitis/prostatitis/ urethritis.  Urology  69(Suppl. 4): 9–16. Payne, H., Adamson, A., Bahl, A., Borwell, J., Dodds,  D., Heath, C.  et al . (2013) Chemical- and radiation- induced haemorrhagic cystitis: current treatments and  challenges.  BJU Int  112: 885–897. Porru, D., Cervigni, M., Nasta, L., Natale, F., Lo  Voi, R., Tinelli, C.  et al . (2008) Results of endovesical  hyaluronic acid/chondroitin sulfate in the treatment  of interstitial cystitis/painful bladder syndrome.  Rev  Recent Clin Trials  3: 126–129. Porru, D., Leva, F., Parmigiani, A., Barletta, D.,  Choussos, D. and Gardella, B. (2012) Impact of  intravesical hyaluronic acid and chondroitin sulphate  on bladder pain syndrome/interstitial cystitis.  Int  Urogynecol J  23: 1193–1199. Sculptoreanu, A., de Groat, W., Buffington, C. and  Birder, L. (2005) Abnormal excitability in capsaicin- responsive DRG neurons from cats with feline  interstitial cystitis.  Exp Neurol  193: 437–443. Serretta, V. (2014) Fibronectin (FN), epidermal  growth factor-receptor (EGF-R) and heparin- binding epidermal growth factor-like (HB-EGF)  urinary expressions and topical toxicity of adjuvant  intravesical therapy for nonmuscle invasive bladder  cancer (NMI-BC).  Eur Urol Suppl  13: e409. Shao, Y., Lu, G. and Shen, Z. (2012) Comparison of  intravesical hyaluronic acid instillation and hyperbaric  oxygen in the treatment of radiation-induced  hemorrhagic cystitis.  BJU Int  109: 691–694. Sommariva, M., Lazzeri, M., Abrate, A., Guazzoni,  G., Sandri, S. and Montorsi, F. (2014) Intravescial  hyaluronic acid and chondroitin sulphate improve  symptoms and quality of life in patients with late  radiation tissue cystitis: an investigative pilot study.  Eur J Inflammation  12: 177–185. Sorlozano, A., Jimenez-Pacheco, A., de Dios Luna  Del Castillo, J., Sampedro, A., Martinez-Brocal, A.,  Miranda-Casas, C.  et al . (2014) Evolution of the  resistance to antibiotics of bacteria involved in urinary  tract infections: a 7-year surveillance study.  Am J  Infect Control  42: 1033–1038. Steinhoff, G., Ittah, B. and Rowan, S. (2002) The  efficacy of chondroitin sulphate 0.2% in treating  interstitial cystitis.  Can J Urol  9: 1454–1458. Topazio, L., Miano, R., Maurelli, V., Gaziev, G.,  Gacci, M., Iacovelli, V.  et al . (2014) Could hyaluronic  acid (ha) reduce bacillus calmette-guerin (BCG) local  side effects? Results of a pilot study.  BMC Urol  14: 64. Torella, M., Schettino, M., Salvatore, S., Serati,  M., De Franciscis, P. and Colacurci, N. (2013)  Intravesical therapy in recurrent cystitis: a multi- center experience.  J Infect Chemother  19: 920–925. Yoon, H., Byun, Y., Shim, B., Chung, W., Lee, D.  and Parl, Y. (2013) Early experience of safety and  efficacy of sodium hyaluronate-chondroitin sulfate  solution in chronic painful conditions in the bladder.  Eur Urol Suppl  12: e512. Visit SAGE journals online   http://tau.sagepub.com SAGE journals </p>
                                        
                                            <p>8. Therapeutic Advances in Urology  8(2)  98   http://tau.sagepub.com who underwent instillation with combined sodium  hyaluronic acid-chondroitin sulphate (Ialuril®).  Urol  Int  91: 81–88. Creta, M., Di Meo, S., Buonopane, R. and  Imperatore, V. (2012) Intravesical administration of  hyaluronic acid and chondroitin sulphate for bacillus  Calmette-Guerin induced chemical cystitis. 85th  Italian Society of Urology Congress, 21–24 October  2012, Venice, Italy: poster P164. Damiano, R., Quarto, G., Bava, I., Ucciero, G., De  Domenico, R., Palumbo, M.  et al . (2011) Autorino,  R. Prevention of recurrent urinary tract infections  by intravesical administration of hyaluronic acid  and chondroitin sulphate: a placebo-controlled  randomised trial.  Eur Urol  59: 645–651. De Vita, D. and Giordano, S. (2012) Effectiveness  of intravesical hyaluronic acid/chondroitin sulfate in  recurrent bacterial cystitis: a randomized study.  Int  Urogynecol J  23: 1707–1713. De Vita, D., Giordano, S. and Coppola, E. (2010)  Prospective observational study of intravesical sodium  hyaluronate and chondroitin sulfate in women  with chronic cystitis, recurrent bacterial cystitis:  preliminary data. 86th SIGO Congress, 14–17  November 2010, Milan, Italy. Dinis, P., Charrua, A., Avelino, A., Yaqoob, M.,  Bevan, S., Nagy, I.  et al . (2004) Anandamide-evoked  activation of vanilloid receptor 1 contributes to the  development of bladder hyperreflexia and nociceptive  transmission to spinal dorsal horn neurons in cystitis.  J Neurosci  24: 11253–11263. Doyle, C., Palmer, J., Munglani, R. and Hunt, S.  (1997) Molecular consequences of noxious stimulation.  In: Borsook, D. (ed.),  Molecular Neurobiology of Pain ,  Progress in Pain Research and management, Vol. 9.  Seattle, WA: IASP Press, pp. 145–170. Engelhardt, P., Morakis, N., Daha, L., Esterbauer,  B. and Riedl, C. (2011) Long-term results of  intravesicalhyaluronan therapy in bladder pain  syndrome/interstitial cystitis.  Int Urogynecol J  22:  401–405. European Association of Urology (2015)  EAU  guidelines: the best current evidence for clinical practice .  Available at: www.uroweb.org/guidelines (accessed 27  November 2015). Foxman, B. (2002) Epidemiology of urinary tract  infections: incidence, morbidity, and economic costs.  Am J Med  113(Suppl. 1A): 5s–13s. Gacci, M., Saleh, O., Giannessi, C., Detti, B., Livi,  L., Monteleone Pasquetti, E.  et al . (2015) Sodium  hyaluronate and chondroitin sulfate replenishment  therapy can improve nocturia in men with post- radiation cystitis: results of a prospective pilot study.  BMC Urol  15: 65. Giannessi, C., Villari, D., Saleh, O., Frizzi, J., Raugel,  A., Li Marzi, V.  et al . (2014) Nocturia related to  post radiation bladder pain can be improved by  hyaluronic acid chondroitin sulfate (Ialuril®).  Eur Urol   13(Suppl.): e592. Giberti, C., Gallo, F., Cortese, P. and Schenone, M.  (2013) Combined intravesical sodium hyaluronate/ chondroitin sulfate therapy for interstitial cystitis/ bladder pain syndrome: a prospective study.  Ther Adv  Urol  5: 175–179. Guay, D. (2008) Contemporary management of  uncomplicated urinary tract infections.  Drugs  68:  1169–1205. Han, X., Wu, X., Li, B., Pan, F., Li, W., Liu, S.,  Zeng, F.  et al . (2015) The effects of intravesical  therapy with hyaluronic acid for painful bladder  syndrome: preliminary Chinese experience and  systematic review.  Taiwan J Obstet Gynecol  54:  240–247. Hanno, P., Baranowski, A. and Fall, M. (2005)  Painful bladder syndrome (including interstitial  cystitis). In: Abrams, P., Wein, A. and Cardozo, L.  (eds),  Incontinence , 3rd edn. Paris: Health Publications  Limited, pp. 1456–1520. Hanno, P., Burks, D., Clemens, J., Dmochowski,  R., Erickson, D., Fitzgerald, M.  et al . (2011)  AUA guideline for the diagnosis and treatment of  interstitial cystitis/bladder pain syndrome.  J Urol  185:  2162–2170. Hurst, R., Roy, J., Min, K., Veltri, R., Marley, G.,  Patton, K.  et al . (1996) A deficit of chondroitin  sulfate proteoglycans on the bladder uroepithelium in  interstitial cystitis.  Urology  48: 817–821. Iavazzo, C., Athanasiou, S., Pitsouni, E. and Falagas,  M. (2007) Hyaluronic acid: an effective alternative  treatment of interstitial cystitis, recurrent urinary tract  infections, and hemorrhagic cystitis?  Eur Urol  51:  1534–1540. Imperatore, V., Certa, M., Di Meo, S.,  Buonopane, R., Fusco, F., Imbimbo, C.  et al .  (2014) Intravesical instillation of sodium  hyaluronate–chondroitin sulfate in patients with  bacillus calmette-guérin-induced chemical cystitis  unresponsive to conventional therapies: preliminary  experience with 1 year follow-up.  Eur Urol Suppl  13:  e466. Laupland, K., Ross, T., Pitout, J., Church, D. and  Gregson, D. (2007) Community-onset urinary tract  infections: a population-based assessment.  Infection   35: 150–153. Lazzeri, M. (2009) Editorial comment on: a refocus  on the bladder as the originator of storage lower  urinary tract symptoms: a systematic review of the  latest literature.  Eur Urol  56: 820. </p>
                                        
                                            <p>6. Therapeutic Advances in Urology  8(2)  96   http://tau.sagepub.com radiation bladder pain [Giannessi  et  al.  2014].  This study evaluated the impact of HA  +  CS on  symptoms and bother related to nocturia in men  with PBS. The authors concluded that HA  +  CS  was effective in reducing nocturia and related  bother after radiotherapy. Gacci and colleagues  confirmed such results [Gacci  et   al.  2015].  Although bladder instillation treatment with a  combination of HA and CS can be considered  effective in reducing nocturnal voiding frequency  in men with post radiation bladder pain for pros - tate cancer (PCa), RCTs with sham treatment are  needed to extend and validate results. BCG-induced chemical cystitis unresponsive to  conventional therapies represents a considerable  challenge for clinicians. While BCG is considered  to be an effective treatment to reduce the recur - rence and progression of nonmuscle invasive  bladder cancer (NMIBC), it is indeed associated  with local treatment-related side effects that can  lead to discontinuation or interruption. Imperatore and colleagues investigated treatment  of BCG-induced chemical cystitis unresponsive  to traditional treatments with intravesical admin - istration of HA  +  CS [Imperatore  et al.  2014]. At  Table 1.   Clinical evidence of exogenous glycosaminoglycans treatment for cystitis. Condition Number of patients (treatment) Reference UTIs 157 (HA/CS) Cicione  et al . [2014] UTIs 23(Fosfomycin) Torella  et al . [2013]   22 (HA/CS)     24 (Ialuril ®   +  Fosfomycin)   UTIs 14 (HA/CS)  versus  14 (control) De Vita and Giordano [2012] UTIs 28 (HA/CS)  versus  28 (placebo) Damiano  et al . [2011] PBS/IC 19 (HA/CS) Morelli  et al . [2015] PBS/IC 20 (HA/CS) Giberti  et al . [2013] PBS/IC and UTIs 12 UTIs  +  9 IC/PBS (HA/CS) Costantini  et al .·[2013] . PBS/IC 22 (HA/CS) Porru  et al . [2012] PBS/IC 12 (HA/CS) Cervigni  et al . [2012] PBS/ICand UTIs 13 UTIs  +  17 IC/PBS (HA/CS) Bassi  et al . [2011] PBS/IC 23 (HA/CS) Porru,  et al . [2008] PBS/IC 23 (HA/CS) Cervigni  et al . [2008] Cystitis after external radiotherapy for  prostate cancer (PCa) 23 (HA/CS) Gacci  et al . [2015 Late radiation tissue cystitis (LRTC) 27 (HA/CS) Sommariva  et al.  [2014] PBS/IC 73 IC/PBS (HA/CS)  versus  35 IC/ PBS (DMSO) Cervigni  et al . [2014] Recurrent bacterial cystitis 99 patients antibiotics  versus  112  patients (HA/CS) Adile  et al . [2014] Mitomycin, epirubicin or BCG-induced  chemical cystitis 55 asymptomatic patients (HA/CS) Serretta [2014]   10 volunteers control   PBS/IC 73 IC/PBS (HA/CS)  versus  35 IC/ PBS (DMSO) Cervigni  et al . [2014] PBS due to pelvic irradiation for locally  advanced prostate cancer 23 radiation cystitis (HA/CS) Giannessi  et al . [2014] BCG-induced chemical cystitis 15 chemical cystitis (HA/CS) Imperatore  et al . [2014] Chronic cystitis and PBS/IC 15 chronic cystitis  +  16 IC/PBS  (HA/CS) Yoon  et al . [2013] BCG-induced chemical cystitis 24 (HA/CS) Li Marzi  et al . [2013] BCG-induced chemical cystitis 15 (HA/CS) Creta  et al . [2012] BCG, Bacillus Calmette-Guérin; CS, chondroitin sulfate; HA, hyaluronic acid; IC, interstitial cystitis; PBS, painful bladder syndrome; UTI, urinary  tract infection. </p>
                                        
                                            <p>4. Therapeutic Advances in Urology  8(2)  94   http://tau.sagepub.com bacterial cystitis in the previous year [Damiano  et al.  2011]. Earlier observational studies showing that exoge - nous intravesical HA markedly reduced recur - rences of UTIs [Constantinides  et   al.  2004;  Lipovac  et al.  2007] were followed by a prospec - tive study of the combination of HA and CS in  patients with recurrent UTIs [Damiano  et  al.   2011]. This randomized, double-blind, placebo- controlled trial of Ialuril (four instillations at  weekly intervals, then five instillations at monthly  intervals) monitored 28 patients randomized to  Ialuril and 29 patients randomized to placebo for  12 months. Patients treated with active drug had  fewer UTI recurrences, a longer time to recur - rence and a greater improvement in quality of life  than patients in the placebo group. They experi - enced fewer UTI episodes and a longer mean time  to recurrence than patients receiving placebo  (87%  versus  10% and 185  versus  53 days;  p   &lt;  0.05  for both); the total number of UTIs experienced  at 6 and 12 months was also significantly less ( p   &lt;   0.05) in the Ialuril group. Symptoms (according  to the pelvic pain, urgency and frequency score)  improved significantly and quality of life was  improved as well through 12 months ( p   &lt;  0.001). De Vita and colleagues compared exogenous  intravesical GAGs to antibiotic prophylaxis for  recurrent UTIs in 28 women; the intravesical  treatment significantly reduced the recurrence of  UTIs and improved urinary symptoms, quality of  life and cystometric capacity at 12 months follow  up [De Vita  et  al.  2010]. Results in the GAGs  (Ialuril) and antibiotic groups were: number of  recurrences (1  versus  2.3;  p  = 0.02), mean 3-day  voiding (17.8  versus  24.2;  p  = 0.04), symptoms  according to visual analogue scale score (pain 1.6  versus  7.8;  p   &lt;  0.001), Pelvic Pain and Urgency/ Frequency Symptom Scale (PUF) score (11.2  versus  19.6;  p   &lt;  0.001), King’s Health  Questionnaire (KHQ) score (18.4  versus  47.3;  p   &lt;  0.001) and maximum cystometric capacity  (380  versus  229 ml;  p   &lt;  0.001). As in the Damiano  study, tolerability of the Ialuril formulation was  good, with no serious adverse events reported.  Recently Cicione and colleagues [Cicione  et  al.   2014] assessed the effectiveness of intravesical  instillation of HA and CS as a nonantibiotic treat - ment option for the prophylaxis of recurrent UTIs  in female patients at seven European institutions.  They used intravesical instillations of 50 ml HA  1.6% and CS 2% solution in 157 women with  recurrent UTIs. UTI episodes decreased from  4.13  ±  1.14 to 0.44  ±  0.50 ( p  = 0.01) at 12  months, while recurrent UTI time increased from  94.8  ±  25.1 days to 178.4  ±  37.3 days (p = 0.01)  at 12 months. An improvement in symptoms and  quality of life was achieved. In conclusion, restoring GAG bladder layer ther - apy seems to be a promising nonantibiotic ther - apy to prevent recurrent UTIs. Painful bladder syndrome/interstitial cystitis To improve the integrity and function of the blad - der lining, exogenous intravesical GAG replace - ment therapies are one of the treatment options  for patients with PBS/IC, generally refractory to  conventional therapy [European Association of  Urology, 2015]. There are four different commer - cially available products for GAG replenishment  including CS, heparin, HA and pentosanpolysul - fate. Each product has different concentrations  and dosage formulations. A combination of CS  and HA is the latest commercially available prod - uct. Exogenous intravesical HA was the first GAG  used for the treatment of PBS/IC, followed by  other different commercially available products  for GAG replenishment including CS, heparin,  HA and pentosanpolysulfate. The combination of  CS and HA (Ialuril, IBSA) is the latest commer - cially available product. Morales and colleagues found a complete or par - tial response rate of 71% for up to 1 year [Morales  et al.  1996]. Recently Engelhardt and colleagues  observed a 50% complete bladder symptom  remission after intravesical HA. Those patients  who responded did not use additional therapy  during the 5-year follow up; 41.7% with symp - tom recurrence improved with HA maintenance  [Engelhardt  et  al.  2011]. Hanno and colleagues  reached a different conclusion [Hanno  et  al.   2005]. They carried out a double-blind, placebo- controlled, multicentre clinical study of different  HA preparations (40 or 200 mg/cc) and did not  find any significant efficacy of sodium hyaluro - nate compared with placebo. Steeinhoff and colleagues investigated the exoge - nous CS therapy efficiency through an open-label  12-month study. They found a response rate for  symptom improvement of 67% in 18 patients  with 40 ml instillations of CS 0.2% weekly for 4  weeks and then monthly for 12 months [Steinhoff  et  al.  2002]. A recently published randomized,  controlled trial (RCT) failed to show superiority  </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1388</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1047</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">341</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    4
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">24</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">20</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">1</span>
                                                    193.111.224.53
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1472 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1384 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1463 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1303 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1361 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1298 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1413 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1367 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1220 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1250 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1309 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1357 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/37/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections- bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1239 Views . <timeago class="timeago" datetime="2019-10-31 13:46:36.042595"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1773 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1618 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="335a5d555c735b51401d5b46">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:22 GMT -->
</html>
    
    
